Abstract：In recent years, great progress has been made in the treatment outcome of childhood acute leukemia with the improvement of chemotherapy regimens and the introduction of risk-stratified therapy; however, minimal residual disease (MRD) is still a difficult problem which affects the prognosis of acute leukemia. MRD influences the selection of chemotherapy regimens and recurrence risk stratification, and meanwhile, it can be used for prognostic prediction. At present, flow cytometry and polymerase chain reaction are mainly used for MRD detection. The next-generation sequencing also plays an important role in MRD detection, especially in MRD detection after stem cell transplantation. This article reviews the methodology and significance of MRD detection in childhood acute leukemia.
Bartram J, Wade R, Vora A, et al. Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up:results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003[J]. Arch Dis Child, 2016, 101(5):449-454.
[2]
Athale UH, Gibson PJ, Bradley NM, et al. Minimal residual disease and childhood leukemia:standard of care recommendations from the Pediatric Oncology Group of Ontario MRD Working Group[J]. Pediatr Blood Cancer, 2016, 63(6):973-982.
[3]
Campana D. Progress of minimal residual disease studies in childhood acute leukemia[J]. Curr Hematol Malig Rep, 2010, 5(3):169-176.
Denys B, van der Sluijs-Gelling AJ, Homburg C, et al. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia[J]. Leukemia, 2013, 27(3):635-641.
[6]
Karawajew L, Dworzak M, Ratei R, et al. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia[J]. Haematologica, 2015, 100(7):935-944.
[7]
Cheng SH, Lau KM, Li CK, et al. Minimal residual disease-based risk stratification in Chinese childhood acute lymphoblastic leukemia by flow cytometry and plasma DNA quantitative polymerase chain reaction[J]. PLoS One, 2013, 8(7):e69467.
Rocha JM, Xavier SG, de Lima Souza ME, et al. Current strategies for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.[J]. Mediterr J Hematol Infect Dis, 2016, 8(1):e2016024.
[10]
Gandemer V, Pochon C, Oger E, et al. Clinical value of pretransplant minimal residual disease in childhood lymphoblastic leukaemia:the results of the French minimal residual diseaseguided protocol[J]. Br J Haematol, 2014, 165(3):392-401.
[11]
Campana D. Minimal residual disease[J]. Leukemia Supplements, 2012(1):S3-S4.
[12]
Campana D, Coustan-Smith E. Measurements of treatment response in childhood acute leukemia[J]. Korean J Hematol, 2012, 47(4):245-254.
[13]
Brüggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials:Proceedings of the Second International Symposium on MRD Assessment in Kiel, Germany, 18-20 September 2008[J]. Leukemia, 2010, 24(3):521-535.
[14]
Anthias C, Dignan FL, Morilla R, et al. Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML[J]. Bone Marrow Transplant, 2014, 49(5):679-683.
[15]
Martelli MP, Sportoletti P, Tiacci E, et al. Mutational landscape of AML with normal cytogenetics:Biological and clinical implications[J]. Blood Rev, 2013, 27(1):13-22.
[16]
Baraka A, Sherief LM, Kamal NM, et al. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flow cytometry[J]. Int J Hematol, 2017, 105(6):784-791.
Getta BM, Devlin SM, Levine RL, et al. Multicolor flow cytometry and multigene next-generation sequencing are complementary and highly predictive for relapse in acute myeloid leukemia after allogeneic transplantation[J]. Biol Blood Marrow Transplant, 2017, 23(7):1064-1071.
[19]
Balduzzi A. Minimal residual disease assessment by nextgeneration sequencing. Better tools to gaze into the crystal ball?[J]. Bone Marrow Transplant, 2017, 52(7):952-954.
Coustan-Smith E, Campana D. Immunologic minimal residual disease detection in acute lymphoblastic leukemia:a comparative approach to molecular testing[J]. Best Pract Res Clin Haematol, 2010, 23(3):347-358.
[22]
Coustan-Smith E, Sancho J, Hancock ML. Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia[J]. Blood, 2002, 100(7):2399-2402.
Malagola M, Skert C, Borlenghi E, et al. Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients[J]. Cancer Med, 2016, 5(2):265-274.
[25]
Wang L, Gao L, Xu S, et al. High prognostic value of minimal residual disease detected by flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor acute myeloid leukemia (CBF-AML)[J]. Ann Hematol, 2014, 93(10):1685-1694.
[26]
Kotrova M, van der Velden VHJ, van Dongen JJM, et al. Nextgeneration sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL[J]. Bone Marrow Transplant, 2017, 52(7):962-968.
[27]
Sekiya Y, Xu Y, Muramatsu H, et al. Clinical utility of nextgeneration sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia[J]. Br J Haematol, 2017, 176(2):248-257.
[28]
Wu D, Emerson RO, Sherwood A, et al. Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH[J]. Clin Cancer Res, 2014, 20(17):4540-4548.
[29]
Schrappe M, Valsecchi MG, Bartram CR, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL:results of the AIEOP-BFM-ALL 2000 study[J]. Blood, 2011, 118(8):2077-2084.
Vora A, Goulden N, Wade R, et al. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003):a randomised controlled trial[J]. Lancet Oncol, 2013, 14(3):199-209.
[32]
Pui C, Pei D, Coustan-Smith E, et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia:a prospective study[J]. Lancet Oncol, 2015, 16(4):465-474.
[33]
Eckert C, Hagedorn N, Sramkova L, et al. Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia:prognostic relevance of early and late assessment[J]. Leukemia, 2015, 29(8):1648-1655.
[34]
Salah-Eldin M, Abousamra NK, Azzam H. Clinical significance of minimal residual disease in young adults with standard-risk/Ph-negative precursor B-acute lymphoblastic leukemia:results of prospective study[J]. Med Oncol, 2014, 31(5):938.
[35]
Karol SE, Coustan-Smith E, Cao X, et al. Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy[J]. Br J Haematol, 2015, 168(1):94-101.
[36]
Umeda K, Iwai A, Kawaguchi K, et al. Impact of post-transplant minimal residual disease on the clinical outcome of pediatric acute leukemia[J]. Pediatr Transplant, 2017, 21(4):e12926.
Balduzzi A, Di Maio L, Silvestri D, et al. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia:is there any room for intervention?[J]. Br J Haematol, 2014, 164(3):396-408.
[39]
Leung W, Pui CH, Coustan-Smith E, et al. Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with veryhigh-risk leukemia[J]. Blood, 2012, 120:468-472.
[40]
Fronkova E, Muzikova K, Mejstrikova E, et al. B-cell reconstitution after allogeneic SCT impairs minimal residual disease monitoring in children with ALL[J]. Bone Marrow Transplant, 2008, 42(3):187-196.
[41]
Bernal T, Diez-Campelo M, Godoy V, et al. Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome[J]. Leuk Res, 2014, 38(5):551-556.
